Search ATRC
AtriCure, Inc.
Nasdaq · CIK 1323885
Last close55.14
Daily change+1.55 (2.89%)
10 Years gain+253.24%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ATRC · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
57.8Momentum
87.6Acceleration
87.6Confidence
85.0Annual Revenue17
Quarterly Revenue73
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.9 / 25
Quality19.6 / 25
Capital Efficiency0.4 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.4099 percentage points.
Operating leverageOperating margin improved by 7.5115 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM21.65%OK
Revenue CAGR 3Y17.4%OK
Gross Margin76.2%OK
Operating Margin0.74%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC0.7%OK
Incremental Operating Margin 3Y23.63%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.11%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $534.53M | $400.78M | -$9.45M | $57.33M | $48.28M | 74.98% | -1.77% | 9.03% | -1.9% | 47.75M |
| 2025 FY Dec 31, 2024 | $465.31M | $347.52M | -$40.01M | $12.20M | $745,000.00 | 74.69% | -8.6% | 0.16% | -8.01% | 46.97M |
| 2025 FY Dec 31, 2023 | $399.25M | $300.37M | -$26.68M | $4.48M | -$7.51M | 75.23% | -6.68% | -1.88% | -5.37% | 46.31M |
| 2024 FY Dec 31, 2022 | $330.38M | $245.94M | -$42.67M | -$22.14M | -$39.02M | 74.44% | -12.92% | -11.81% | -8.22% | 45.74M |
| 2023 FY Dec 31, 2021 | $274.33M | $205.86M | $55.21M | -$13.78M | -$23.53M | 75.04% | 20.12% | -8.58% | 16.85% | 46.04M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $565.26M | sum latest 4 fiscal quarters Revenue | OK | 0001323885-26-000035, 0001323885-25-000103 |
| Revenue Growth TTM | 21.65% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001323885-26-000035, 0001323885-25-000103 |
| Revenue CAGR 3Y | 17.4% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001323885-26-000007 |
| Revenue CAGR 5Y | 20.95% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001323885-26-000007 |
| Gross Profit CAGR 3Y | 17.68% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001323885-26-000007 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001323885-26-000035, 0001323885-25-000103 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 76.2% | Gross Profit / Revenue | OK | 0001323885-26-000035, 0001323885-25-000103 |
| Operating Margin | 0.74% | Operating Income / Revenue | OK | 0001323885-26-000035, 0001323885-25-000103 |
| ROIC | 0.7% | NOPAT / Average Invested Capital | OK | 0001323885-26-000035, 0001323885-25-000103 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001323885-26-000035 |
| Current Ratio | 4.22x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 2.75x | (Cash + Short-term Investments) / Total Debt | OK | 0001323885-26-000035 |
| Revenue per Diluted Share | $11.57 | Revenue / Diluted Shares | OK | 0001323885-26-000035, 0001323885-25-000103 |